Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Analyst Ratings
Moderate Buy
5 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IOVA Stock 12 Month Forecast
Average Price Target
$9.50
▲(292.56% Upside)
| Highest Price Target$20.00 | Average Price Target$9.50 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$2.5
Hold
3.31%
Upside
Reiterated
08/27/25
H.C. Wainwright
$20
Buy
726.45%
Upside
Reiterated
08/19/25
Iovance Biotherapeutics' Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth PotentialValuation and impediments to achieving price target. We reiterate our Buy rating and $20 price target. Our price target is based on our clinical net present value (NPV) model, which derives its primary value from AMTAGVI for metastatic melanoma (46%) and lifileucel for endometrial cancer (10%), NSCLC (23% contribution), and for 1L advanced melanoma (21%). This model allows us to flex multiple assumptions affecting a drug's potential commercial profile.
Chardan Capital
$20
Buy
726.45%
Upside
Reiterated
08/08/25
Updating our model for 2Q25 financials and these updates shifts our PT to $20.
Wells Fargo
$18→$14
Buy
478.51%
Upside
Reiterated
08/08/25
Barclays
$4
Buy
65.29%
Upside
Reiterated
08/08/25
Truist Financial
―
Hold
―
Reiterated
08/08/25
TD Cowen
$5
Buy
106.61%
Upside
Reiterated
08/07/25
Goldman Sachs
$1
Sell
-58.68%
Downside
Downgraded
07/15/25
Citizens JMP
―
Hold
―
Reiterated
07/15/25
UBS
$2
Hold
-17.36%
Downside
Downgraded
05/16/25
Robert W. Baird
$20→$3
Hold
23.97%
Upside
Downgraded
05/09/25
Mizuho Securities
$30→$10
Buy
313.22%
Upside
Reiterated
05/09/25
Stifel Nicolaus
$18
Buy
643.80%
Upside
Reiterated
03/17/25
Jefferies
$23→$18
Buy
643.80%
Upside
Reiterated
03/13/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$2.5
Hold
3.31%
Upside
Reiterated
08/27/25
H.C. Wainwright
$20
Buy
726.45%
Upside
Reiterated
08/19/25
Iovance Biotherapeutics' Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth PotentialValuation and impediments to achieving price target. We reiterate our Buy rating and $20 price target. Our price target is based on our clinical net present value (NPV) model, which derives its primary value from AMTAGVI for metastatic melanoma (46%) and lifileucel for endometrial cancer (10%), NSCLC (23% contribution), and for 1L advanced melanoma (21%). This model allows us to flex multiple assumptions affecting a drug's potential commercial profile.
Chardan Capital
$20
Buy
726.45%
Upside
Reiterated
08/08/25
Updating our model for 2Q25 financials and these updates shifts our PT to $20.
Wells Fargo
$18→$14
Buy
478.51%
Upside
Reiterated
08/08/25
Barclays
$4
Buy
65.29%
Upside
Reiterated
08/08/25
Truist Financial
―
Hold
―
Reiterated
08/08/25
TD Cowen
$5
Buy
106.61%
Upside
Reiterated
08/07/25
Goldman Sachs
$1
Sell
-58.68%
Downside
Downgraded
07/15/25
Citizens JMP
―
Hold
―
Reiterated
07/15/25
UBS
$2
Hold
-17.36%
Downside
Downgraded
05/16/25
Robert W. Baird
$20→$3
Hold
23.97%
Upside
Downgraded
05/09/25
Mizuho Securities
$30→$10
Buy
313.22%
Upside
Reiterated
05/09/25
Stifel Nicolaus
$18
Buy
643.80%
Upside
Reiterated
03/17/25
Jefferies
$23→$18
Buy
643.80%
Upside
Reiterated
03/13/25
Best Analysts Covering Iovance Biotherapeutics
1 Month
xxx
Success Rate
13/29 ratings generated profit
Average Return
+0.04%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 44.83% of your transactions generating a profit, with an average return of +0.04% per trade.
3 Months
xxx
Success Rate
10/17 ratings generated profit
Average Return
+11.87%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +11.87% per trade.
1 Year
2 Years
xxx
Success Rate
3/17 ratings generated profit
Average Return
-42.38%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 17.65% of your transactions generating a profit, with an average return of -42.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IOVA Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
15
16
14
15
13
Buy
3
1
1
1
1
Hold
3
9
12
20
23
Sell
0
1
1
2
1
Strong Sell
0
0
0
0
0
total
21
27
28
38
38
Each month's total comprises the sum of three months' worth of ratings.
IOVA Financial Forecast
IOVA Stock Forecast FAQ
What is IOVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 9.50.
What is IOVA’s upside potential, based on the analysts’ average price target?
Iovance Biotherapeutics Inc has 292.56% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IOVA a Buy, Sell or Hold?
Iovance Biotherapeutics Inc has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 1 sell ratings.
What is Iovance Biotherapeutics Inc’s price target?
The average price target for Iovance Biotherapeutics Inc is 9.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $1.00. The average price target represents 292.56% Increase from the current price of $2.42.
The highest analyst price target is $20.00 ,the lowest forecast is $1.00. The average price target represents 292.56% Increase from the current price of $2.42.
What do analysts say about Iovance Biotherapeutics Inc?
Iovance Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of IOVA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.